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Abstract.  Several studies have addressed the interac- 
tion of the HIV Tat protein with the cell surface.  Our 
analysis of the cell attachment-promoting  activity of 
Tat and peptides derived from it revealed that the basic 
domain of Tat,  not the arg-gly-asp (RGD) sequence, is 
required for cell attachment to Tat.  Affinity chroma- 
tography with Tat peptides and immunoprecipitation 
with various anti-integrin  antibodies suggest that the 
vitronectin-binding  integrin,  cxv/35, is the cell surface 
protein that binds to the basic domain of Tat.  The Tat 
basic domain contains the sequence RKKRRQRRR. A 
related sequence, KKQRFRHRNRKG, present in the 
heparin-binding  domain of an aviS5 ligand, vitronectin, 
also bound c~,/35 in affinity chromatography and,  in 
combination with an RGD peptide, was an inhibitor of 
cell attachment to vitronectin.  The a~/35 interaction 
with these peptides was not solely due to high content 
of basic amino acids in the ligand sequences; tXv/35  did 
not bind substantially to peptides consisting entirely of 
arginine or lysine, whereas a/3t integrin did bind to 
these peptides. The interaction of c~v/35 with Tat is 
atypical for integrins  in that the binding to Tat is diva- 
lent cation independent,  whereas the binding of the 
same integrin to an RGD-containing peptide or to 
vitronectin requires divalent cations.  These data define 
an auxiliary integrin binding specificity for basic 
amino acid sequences. These basic domain binding 
sites may function synergistically with the binding sites 
that recognize RGD or equivalent sequences. 
T 
H~  tripeptide  arg-gly-asp  (RGD) 1 is  required  for 
cell adhesion to a number of proteins,  including fibro- 
nectin, vitronectin,  and fibrinogen (Pierschbacher and 
Ruoslahti,  1984; Ruoslahti  and Pierschbacher,  1987). This 
adhesion is mediated by integrins, a family oftransmembrane 
receptors composed of two subunits, ot and/3 (Hemler,  1990; 
Ruoslahti,  1991; Hynes,  1992). 
The Tat protein of human immunodeficiency virus (HIV-1) 
contains an RGD sequence and can mediate cell attachment 
in an RGD-dependent manner (Brake et al., 1990). Extracel- 
lular Tat is internalized  by cells and transported to the nu- 
cleus, where it retains  the ability to transactivate  the HIV 
promoter (Frankel and Pabo, 1988). Furthermore, extracel- 
lular Tat has been shown to modulate cell proliferation,  both 
in the suppression of  proliferation  of  antigen-activated T-cells 
(Viscidi et al., 1989) and in the stimulation  of proliferation 
of Kaposi's sarcoma (KS)-derived cells (Ensoli et al., 1990). 
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We felt that  the possibility of an RGD-binding  integrin 
mediating  some of the interactions  of Tat with cell surfaces 
was of a considerable interest and set out to identify such an 
integrin.  We found that the otvl3~ integrin  bound to the Tat 
protein, but that this interaction was not significant in the up- 
take of Tat by cells. Surprisingly,  our results indicate that the 
binding  of this  integrin  to Tat requires  the basic region, 
whereas the RGD sequence is silent.  We also provide evi- 
dence that  a basic sequence in vitronectin  can serve as a 
binding  site for the av/35 integrin and that the integrin  bind- 
ing requires an appropriate sequence of basic amino acids. 
These results suggest the existence of a previously unrecog- 
nized integrin  specificity directed toward a sequence motif 
consisting  of several basic amino acids. 
Materials and Methods 
Peptide Synthesis 
The intact Tat protein was  synthesized  using t-butoxycarbowyl  (BOC)- 
protected amino acids for stepwise  synthesis  on a solid phase automated 
pepdde synthesizer (model 431A,  Applied Biosystems,  Inc., Foster City, 
CA). Amino acids were added as hydroxybenzotriazole  (HOBO esters using 
n-methylpyrrolidone as the coupling solvent,  The synthesis  was accom- 
plished starting with 0.5 mmol of  Boc-Glu(OBzl)-O-phenylacetamidomethyl 
resin (0.69 g substituted at 0.72 retool) with a minimum of two couplings 
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as determined by a quantitative rtinhydrin  assay.  The cysteine snlthydryls 
were protected with a p-methylbenzyl group to yield a fully-reduced form 
after low/high I-IF cleavage using suitable scavengers. All other peptides 
used were synthesized with a  synthesizer (model 430A, Applied Biosys- 
terns, Inc.) using similar chemistry. The Tat protein sequence: 
1  I0  20  30  40 
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCF  I TKALG I SYGRK 
60  70  80 
KRRQRRRAHQNSQTHQASLSKQPTSQSRGDPTG  PKE, 
(Arya et al., 1985) was used in the peptide syntheses. In the Tat 45-86 pep- 
tide, a  iysine residue was added to the NH2 terminus to facilitate solid 
phase coupling. For the same reason, residue 57 in Tat 5%86 was changed 
from arginine to lysine, and an NH2-terminal cysteine was added to the 
vitronectin basic domain peptide. In Tat 47-58, residue 58 was proline as 
in a variant Tat sequence (Green and Loewenstein, 1988). 
Cell Adhesion 
Cell attachment assays were performed essentially as described (Ruoslahti 
et al., 1982).  Microtiter plates (96 well) were coated with substrate for 1 h 
in the presence of 0.25 % glutaraldehyde. The plates were washed and then 
blocked with 1 M ethanolamine containing 2.5 mg/ml BSA. Subconltuent 
rat L8 or human SK-LMS cells were detached from their substrate with 
trypsin as described (Brake et ai., 1990), washed three times with 0.5 mg/mi 
soybean trypsin inhibitor and resuspended in DME at 106 ceUs/mi. 100 #1 
of cell suspension was added to each well in the presence or absence of in- 
hibitory peptides or antibodies. After a  1-h incubation, the attached cells 
were fixed in 3% paraformaldehyde and stained with 0.5% crystal violet. 
The dye was eluted from the stained cells with 100 #! of 50% ethanol con- 
taining 100  mM sodium citrate (pH 4.2).  Attachment was quantified by 
reading the absorbance at 600 nM. 
Affinity Chromatography 
The Tat-binding proteins were isolated from surface-iodinated cells essen- 
tially as described (Pytela et al., 1985a,b). Cells were detached from cul- 
ture plates in 100 #g/mi trypsin (Sigma Chemical Co., St. Louis, MO) as 
in the cell adhesion assays, and washed three times in 500 #g/rnl soybean 
trypsin inhibitor (Sigma Chemical Co.). Cells were surface iodinated using 
lactoperoxidase and extracted with a buffer containing 150 mM octyl gluco- 
side, 1 mM CaCI2,  1 mM MgCI2,  1 #g/mi aprotinin,  1 #g/mi leupeptin, 
0.4 #g/ml pepstatin, 150 mM NaCI and 50 mM Tris, pH 7.4. The extracts 
were clarified at 15,000 g and passed over a column containing Tat peptides 
coupled to cyanogen bromide-activated Sepharose 413 (Pharmacia LKB Bio- 
technology, Inc., Piscataway,  NJ) or peptides coupled to thiopropyl Sepha- 
rose (Pharmacia LKB Biotechnology, Inc.) through an amino-terminal cys- 
teine. After an incubation of 2  h,  the column was washed with several 
volumes of extraction buffer containing 50 mM octyl glucoside. The bound 
receptor was then eluted with the indicated peptide at a concentration of 
1 mg/ml in the buffer used to wash the column unless otherwise noted. Ali- 
quots were used for immunoprecipitation or were boiled in electrophoresis 
sample buffer and run on 7.5% SDS-polyacrylamide gels. 
Antibodies 
Polyclonal antibodies against the cytoplasmic tails of av,/~3, and t5 were 
raised in rabbits by immunization with synthetic peptides coupled to keyhole 
limpet hemocyanin. The peptides used were KRVRPPQEEQEREQLQPH- 
ENGEGNSET from the COOH terminus of ~v (Suzuki et al., 1986),  KFE- 
EERARAKWDTANNPLYKEATSTFTNITYRGT from the COOH termi- 
nus of/~3 (Fitzgerald et al., 1987), and KKPISTHTVDFTFNKSYNGTVD 
from the COOH-terminus of/35 (Suzuki et al.,  1990).  All peptides were 
synthesized with a  synthesizer (model 430A,  Applied Biosystems, Inc.). 
Additional details on the preparation of some of these antibodies have been 
published (Freed et al., 1989). The anti-Bj  subunit antiserum has also been 
described (Giancotti and  Ruoslahti,  1990).  Each of the antibodies was 
shown to bind to the appropriate integrin subunlt in immunoblotting and 
to immunoprecipitate integrins containing these subunits from various sur- 
face-labeled cell lines. 
Folyclonal antibodies prepared against the Ctv/~3 and ct5/~1 integrins have 
been described (Argraves et al., 1987; Suzuki et al., 1986).  mAbs were a 
gift of Dr. David Cberesh (The Scripps Research Institute, La Jolla, CA) 
(LM 609; Cheresh and Spiro, 1987) or Bristol Myers-Squibb Pharmaceuti- 
cal Research Institute (Seattle, WA) (P3G2; Wayner et al.,  1991). 
Immunoprecipitations 
Immunoprecipitations were performed by incubating material in the pres- 
ence of 5 gl of immunized rabbit serum and 50 #1 protein A Sepharose for 
1 h. The receptor-antibody-protein A complex was spun down and washed 
three times with 0.5% Triton X-100,  150 mM NaC1, 50 mM Tris, pH 7.4. 
The complex was then boiled in electrophoresis sample buffer and loaded 
on 7.5%  SDS-polyacrylamide gels. 
Results 
Cell Adhesion to Tat 
To investigate the mechanism of cell interaction with the Tat 
protein we performed cell attachment assays with a variety 
of Tat derived peptides. L8 rat skeletal muscle cells were 
chosen for these experiments because they had been shown 
to bind to Tat in a previous study (Brake et al.,  1990). In 
agreement with the earlier study (Brake et al.,  1990), L8 
cells readily attached to the Tat protein and to a Tat peptide 
that contained the RGD sequence in addition to the basic do- 
main  (Tat 45-86).  Also  in  agreement with the results  of 
Brake et al. (1990) was that the cells did not spread on the 
surface. An unexpected result was that the cells did not at- 
tach  to  a  shorter peptide  in  which  the  basic  region was 
deleted (Tat 57-86 with residue 57 changed from arginine to 
lysine), even though this peptide contained the cell attach- 
ment sequence RGD (Fig.  1 A).  Similar results were ob- 
tained with the human leiomyosarcoma cell line, SK-LMS 
(Fig.  1 B); the cells bound only to those peptides that con- 
tained the basic region. A peptide containing only the basic 
domain and three flanking amino acids (residues 47-58) sup- 
ported cell attachment  as well as full-length Tat on a molar 
basis even though this peptide did not contain the RGD se- 
quence or the region flanking it. These results, together with 
the result that the attachment  of cells to Tat was inhibited by 
heparin (see Table I), suggest that the basic region of Tat is 
required for cell adhesion, and that the RGD-containing re- 
gion of Tat by itself is incapable of supporting  adhesion of 
the cells tested. 
Isolation and Identification of Tat-binding Proteins 
To  identify the  integrins  or  other cell  surface molecules 
capable of binding to Tat, affinity chromatography was per- 
formed using the 86-amino acid Tat protein and the Tat pep- 
tides.  As was the case in the cell attachment experiments 
shown in Fig.  1, all of the peptides that contained the basic 
domain of Tat were active and gave similar results with the 
L8 and SK-LMS cells. Shown in Fig. 2 are the proteins from 
an iodinated L8 cell extract that bound to the Tat 45-86 pep- 
tide and  eluted with this  peptide or with  full-length Tat. 
Bands of 150 kD and a doublet at "~90 kD were eluted from 
the column. Changing the RGD sequence to KGE (lys-gly- 
glu) or deleting the second exon entirely had no discernible 
effect on the identity of the proteins eluted from the column. 
Even the 12 amino acids comprising the basic domain were 
sufficient to bind and elute these bands (see Fig.  3). How- 
ever,  peptides  lacking  the  basic  domain  did  not  bind 
significant amounts of  iodinated cell surface proteins or elute 
proteins from columns that were active (not shown). 
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Figure 1. Cell adhesion to Tat peptides. Wells of microtiter dishes 
were coated with the indicated concentrations of Tat 1-86 (n), Tat 
45-86  (e),  Tat  5%86  (A),  or  Tat  47-58  (zx). After blocking 
nonspecific binding sites, ,~105 cells were added to each well and 
incubated at  37°C  for  1 h.  The  attached cells were  fixed with 
paraformaldehyde and  stained with crystal violet. The  dye was 
eluted and the absorbance at 600 mn measured in an ELISA reader. 
L8 cells were tested on the first three peptides (A) and SK-LMS 
cells on each of the four peptides (B). Maximum cell attachment 
was  '~8  x  104  cells/well. Each point represents the average of 
three independent experiments. The  standard deviation for each 
point was 0.15 or less. The sequence of the Tat protein used in this 
work is from the HXB-2 strain (Arya et al.,  1985): 
1  10  20  30  40 
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCF  I TKALG I S 
50  6O  70  80 
YGRKKRRQRRRAHQNSQTHQASLSKQPTSQSRGDPTGPKE 
Table L  Adhesion of L8 Cells to  Vitronectin and Tat 
Adhesion of 
L8 cells to  In the presence of 
1 mM  300 nM  0.5 mg/ml  10 mM 
GRGDSP  NaCI  heparin  EDTA 
Vitronectin  -  +  +  - 
Tat  +  -  -  + 
Adhesion assays were performed  as described in Experimental Procedures. 
+  indicates adhesion was significantly  above background binding• -  indicates 
background binding levels of adhesion. 
Immunoprecipitation showed that the material bound to 
the Tat column consisted primarily of integrins. Fig. 3 shows 
an immunoprecipitation of surface-iodinated SK-LMS cell 
proteins  eluted  from  the  Tat  45-86  peptide  column.  The 
column was eluted sequentially with the peptide GRGDSP 
followed by a  12-amino acid peptide containing the basic do- 
main of Tat.  A  small portion of the bound material eluted 
with the peptide GRGDSP and could be immunoprecipitated 
with/3t and B~ antibodies. However, the majority of the ~t 
and  /33  subunit-associated  material  did  not  bind  to  the 
column  and  was  detected in the  unbound  fraction.  These 
results indicate that fl~ and ~3  integrins bind poorly to the 
column despite the presence of an RGD sequence in the pep- 
Figure 2. Affinity chromatography on Tat peptide. Approximately 
5  x  107 rat L8 cells were detached from culture dishes with 0.1 
rng/ml trypsin and washed three times with 0.5 mg/ml soybean tryp- 
sin inhibitor. The cells were iodinated using lactoperoxidase and 
extracted with octylglucoside  (see Materials and Methods). The io- 
dinated L8 cell extract was fractionated on Tat peptide 45-86 cou- 
pled to Sepharose. After washing, the column was eluted with ei- 
ther 1 mg/ml of the Tat peptide or 200/~g/ml of the full-length Tat 
protein. The fractions were analyzed by SDS PAGE (7.5%) under 
nonreducing conditions. 
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matography on Tat peptide. An octylglucoside extract of surface- 
iodinated SK-LMS cells was fractionated on Tat 45-86 coupled to 
Sepharose as described in Materials and Methods. After sequential 
elution with GRGDSE Tat 57-86 and Tat 47-58  (basic 12-mer), 
peak fractions of each eluate were immuuoprecipitated with 5 #l 
of serum containing polyclonal antibodies to the av, /31, /33, or/~5 
subunit  cytoplasmic  domains  and  protein  A  Sepharose.  The 
precipitated proteins were solubilized by boiling in SDS-containing 
sample buffer and analyzed by SDS PAGE (7.5%) under nonreduc- 
ing conditions. Shown are the immunoprecipitations of the flow 
through (unbound), GRGDSP eluate and Tat 47-58 eluate (basic 
12-met). The antibody used is indicated at the top of each lane and 
the subunits are identified on the side. 
tide coupled to the column. They also suggest that the mate- 
rial that remained bound was not bound to the column matrix 
through the RGD  sequence.  However, the material eluted 
with the basic peptide was shown by immunoprecipitation 
with the anti-or,  and anti-/S5 subunit antibodies to contain 
the  otj~5 integrin  (Fig.  3).  The  heterogeneity  of the  /35 
subunit apparent in Figs. 2 and 3 was most likely caused by 
partial proteolysis resulting from harvesting the cells for the 
chromatography with trypsin, since material harvested with 
EDTA did not yield the lower molecular weight band (not 
shown). These results, together with the cell attachment as- 
says, indicate that our test cells bind to the basic domain of 
the Tat protein and that this binding is mediated by the otv/~5 
integrin. 
Comparison of  lntegrins Bound to Tat with Those 
Bound to GRGDSPK Peptide 
Affinity chromatography of the SK-LMS cell extracts on the 
peptide GRGDSPK coupled to Sepharose (Fig. 4) revealed 
Figure 4.  Immunoprecipitation  of material  affinity-purified on 
GRGDSPK Sepharose. An extract of surface-iodinated SK-LMS 
cells was fractionated on GRGDSPK Sepharose as described in 
Materials and Methods. After elution with GRGDSP (1 mg/ml), the 
flow through (unbound) and eluate (bound) was immunoprecipi- 
tated with antibodies to the av,/3~,/33, or/35 subunit cytoplasmic 
domains (see Fig. 3, legend), and analyzed by SDS PAGE (7.5  %) 
under nonreducing conditions. 
a strikingly different pattern than the one obtained with the 
Tat peptide. Whereas the predominant integrin binding to the 
Tat Sepharose was  otJ~5, the otv/33 integrin was  the major 
integrin enriched in the GRGDSPK-bound fraction (Fig. 4). 
Although some a,/~5 was  observed in the bound fraction, 
the majority of this integrin was in the unbound fraction. 
This is in agreement with earlier results showing that otj35 
has  a  relatively weak affinity for the GRGDSPK peptide 
(Freed et al., 1989). Together, these data show that although 
SK-LMS cells contain functional c~,/~3 and  ¢xj35 integrins 
capable  of binding  the  GRGDSPK peptide,  the RGD  se- 
quence in Tat is present in a context unfavorable to the bind- 
ing of these integrins. 
lntegrin Binding to Peptides Consisting Entirely 
of  Basic Amino Acids 
The Tat basic domain contains a single glutamine flanked by 
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of  material affinity purified on 
basic  peptides.  Polyarginine, 
polylysine  (A), and  a  vitro- 
nectin  basic  domain  peptide  (B) 
with the following sequences: 
CRRRRRRRR, CKKKKK- 
KKK, CKKQRFRHRNRKG, 
were  coupled  to  Sepharose, 
and  affinity chromatography 
was performed  as in Fig. 2. 
The bound material was im- 
munoprecipitated with 5 t~l of 
rabbit serum containing anti- 
bodies to the cytoplasmic do- 
mains of the  cx3, otv, /31, B3, 
and B5 integrin  subunits and 
50/zg of protein A Sepharose 
and analyzed by SDS  PAGE 
(7.5%)  under  nonreducing 
conditions. 
two arginine residues on the NH2-terminal side and three 
on the COOH-terminal side. To determine if the otvB5  inter- 
action  was  specific  for  the  Tat basic  domain  or  if tXvB5 
would bind to any arginine-rich peptide, affinity chromatog- 
raphy was also performed with a peptide, CRRRRRRRR, 
consisting  entirely  of  arginine  residues  (with  an  NH2- 
terminal  cysteine added  for coupling).  A  similar  peptide 
consisting entirely of lysine residues was also used (CKK- 
KKKKKK).  The  tx,B5 integrin was  not detectable in  the 
bound fraction from columns containing either of these pep- 
tides (Fig. 5 A). Instead, the B1 subunit was the prominent 
immunoprecipitable integrin subunit from the bound frac- 
tions of both columns. Analysis of the Bt integrins bound to 
these  columns  revealed  that  o~6  and  or5  were  the  major 
subunits bound to the arginine-rich columns and lysine-rich 
columns,  respectively (not  shown),  whereas  ix3 bound to 
both columns (Fig.  5 A). 
Binding of ~j  to a Basic Domain Sequence 
from Vitronectin 
To test whether the interaction of the basic domain of Tat 
with -vB5 was representative of an interaction between txvB5 
and its ligand, vitronectin, affinity chromatography was per- 
formed with a peptide representing a portion of  the vitronec- 
tin  heparin-binding  domain  (CKKQRFRHRNRKG).  The 
results were similar to those with the Tat peptides, except 
that less integrin appeared to bind to the vitronectin peptide 
than  to  Tat.  The  majority  of  the  bound  material  was 
precipitable with or, and B5 antibodies, although some anti- 
Bt-reactive material was also detected (Fig. 5 B). This sug- 
gested that or,B5 can bind to the heparin-binding domain of 
vitronectin in addition to its previously characterized inter- 
action with the RGD sequence of vitronectin (Freed et al., 
1989; Cheresh et al.,  1989). Next, the basic peptides from 
vitronectin and from Tat were used to inhibit cell attachment 
to vitronectin. As shown previously (Cheresh et al.,  1989), 
the GRGDSP peptide was capable of weakly inhibiting the 
otvBs-mediated attachment of cells to vitronectin (Fig.  6). 
Although the basic peptides by themselves were not effective 
inhibitors of L8 cell adhesion to vitronectin, they enhanced 
the  inhibitory activity of GRGDSP when  added together 
with it (Fig. 6). 
Characteristics  of  ¢,13~ Basic Domain Interactions 
To characterize what appeared to be an atypical integrin- 
ligand interaction, we studied the sensitivity of the ccv~/s ba- 
sic sequence interaction to high salt, certain antibodies and 
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Figure 6. Inhibition of cell attachment to vitronectin with peptides. 
L8 cells were allowed to attach to microtiter wells coated with 10 
gg/ml vitronectin in the presence or absence of 0.5 mM GRGDSP 
Tat basic domain peptide, vitronectin (I/N) basic domain peptide, 
or combinations of GRGDSP with one of the basic peptides. At- 
tached cells were fixed and stained as described in Materials and 
Methods.  Maximum cell adhesion was  ,~80%  of the  l0  s cells 
added to each well. Each value represents the average of  three inde- 
pendent experiments. Error bars indicate the standard deviation for 
each point. 
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Figure 8. Inhibition of SK-LMS cell attachment to vitronectin and 
Tat peptide. Approximately  105 SK-LMS cells were added to mi- 
crotiter wells previously coated with 10 #g/ml vitronectin (VN) or 
Tat 45-86 in the presence or absence of  inhibitory antibodies. P3G2 
is a mAb shown previously to inhibit the interaction of u~/35 with 
vitronectin (Wayner et al., 1991). LM 609 inhibits the interaction 
of c~v/33 with vitronectin (Cheresh and Spiro,  1987). Anti-VNR is 
a  polyclonal  antibody  raised  against  the  c~,/53 integrin  purified 
from  a  placental  extract  on  a  GRGDSPK-Sepharose  column 
(Pytela et al., 1987; Freed et al., 1989). P3G2 was culture superna- 
tant diluted 1:2. LM 609 was a partially purified IgG fraction used 
at 3 #g/ml. The anti-VNR is a rabbit serum diluted 1:20. All of  these 
concentrations  were tested for function previously and were not 
toxic to the cells. After a l-h incubation at 37°C, the attached cells 
were fixed and stained as described  above. Each point represents 
the mean of three independent experiments with a standard devia- 
tion smaller than 0.2 absorbance units. 
Figure 7. Elution of integrin from Tat column with EDTA or NaCI. 
Extracts of surface-iodinated  L8 or SK-LMS cells were fraction- 
ated on Tat 45-86 coupled to Sepharose. Sequential elution of the 
columns with  10 mM EDTA (in 100 mM NaC1; lanes 2 and 6), 
250 mM NaCI (lanes 3 and 7) and Tat 45-86 (1 mg/ml; lanes 4 and 
8), followed by immunoprecipitation  with a polyclonal anti-ct~/33 
antibody and analysis by SDS PAGE (7.5%)  under nonreducing 
conditions are shown. Lanes I and 5 are immunoprecipitates of  the 
flow-through material. 
removal of divalent cations. We used the Tat 45-86 peptide 
for these  studies,  because  it bound  otv/35 more effectively 
than the basic peptide from vitronectin.  Integrins typically 
require  divalent  cations  to  bind  their  ligands  and  can be 
eluted from ligand affinity columns with EDTA (Pytela et al., 
1987).  However, the interaction between otv/35 and Tat was 
insensitive to elution with 10 mM EDTA in affinity chroma- 
tography experiments (Fig. 7). Immunoprecipitations of the 
peak fractions eluted with 10 mM EDTA, 250 mM NaC1, or 
the Tat 45-86 peptide with a polyclonal anti-ot~/33 antibody 
revealed  no  o~/35 in  the  EDTA-eluted  fractions,  whereas 
some of it eluted in the high salt fractions and the rest was 
released by the Tat peptide elution. We have also performed 
cell adhesion experiments in the presence of various inhibi- 
tors; the results are summarized in Table I. 
Because the binding of the basic domain peptides to oev/35 
was a novel interaction, we wanted to determine if the basic 
peptides bound to the same site on otv/35 that vitronectin, a 
principal o~v/35 ligand, does. The mAb P3G2 had previously 
been  shown to bind to  uv/35 and  to  inhibit  its  interaction 
with vitronectin (Wayner et al.,  1991).  We were able to re- 
produce this result using SK-LMS cells as shown in Fig.  8. 
However, the mAb did not inhibit the binding of the cells to 
Tat.  Our  polyclonal anti-txv/33 antibody  did  inhibit  the  at- 
tachment of the  SK-LMS cells (Fig.  8)  and  L8  cells (not 
shown) to both Tat and vitronectin, indicating that a receptor 
related to c~v~3 mediates the interaction between SK-LMS 
cells and Tat. A  function-inhibiting mAb recognizing otd33 
(LM 609; Cheresh and Spiro, 1987) did not inhibit the bind- 
ing of the cells to either Tat or vitronectin.  Taken together 
with the affinity chromatography results, these findings indi- 
cate that the attachment of the SK-LMS cells to vitronectin 
is mediated by a~/35 and that two distinct regions in the inte- 
grin are involved, one binding to the RGD region and the 
other to the basic domain. 
Discussion 
The findings reported here identify a  novel interaction be- 
tween integrins and the basic domains of certain adhesive 
proteins. We were led to this observation while working on 
the previously noted ability of certain cells to attach to the 
HIV Tat protein (Brake et al.,  1990). Tat can function as an 
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late cell proliferation (Viscidi et al.,  1989;  Ensoli et al., 
1990),  and the basic region of Tat has been found to be im- 
portant for the binding of Tat to the cell surface (Mann and 
Frankel, 1991). As Tat had previously been claimed to exert 
a  cell attachment-promoting activity through its RGD se- 
quence (Brake et al.,  1990),  integrins were obvious candi- 
dates for mediation of this activity. We found that the ot~/35 
integrin mediates the cell attachment activity of Tat. How- 
ever, anti-integrin antibodies capable of  blocking cell attach- 
ment to Tat were not able to block uptake of Tat into L8 cells 
(our unpublished results), making it unlikely that the ~v/35 
integrin would play a  role in Tat internalization by cells. 
Rather, the interaction of Tat with av/35 appears to be repre- 
sentative of a more general and potentially physiological, ac- 
tivity of the integrins. 
The assignment of ot~/35 as the Tat-binding integrin was 
based on immunological identification: The integrin isolated 
by chromatography on Tat columns from the human SK- 
LMS cells was reactive with antibodies prepared against the 
cytoplasmic domains of the o~, and 135 subunits, and poly- 
clonal antibodies that bind to the  ot~ subunit in  ot~/35 in- 
hibited the attachment of these cells to the Tat-coated sur- 
face. This result agrees with the assumption that the ot~/35 
integrin is the receptor that mediates the attachment of the 
SK-LMS cells to Tat. 
Although the Tat-binding integrin on the human SK-LMS 
cells was identified as otv/35, we were unable to positively 
identify the/3 subunit of the Tat binding integrin from the rat 
L8 cells. It seems likely that this integrin is also o~v/35 be- 
cause it behaved identically to the human C~vl35 integrin in 
the affinity chromatography experiments, and its/3 subunit 
migrated similarly to the human 135 in SDS-PAGE.  How- 
ever, the/3 subunit reacted, at best, weakly with our anti-/~5 
antibodies. These antibodies were prepared against the cyto- 
plasmic peptide of the human/35 subunit and were poorly 
reactive when tested against a number of rat cell lines. Poor 
reactivity of the  antibodies  with  the  rat  135  subunit may 
therefore explain the lack of immunoprecipitation of the L8 
integrin. It is also possible that the/3 subunit of the Tat bind- 
ing integrin from the L8 cells may be an alternatively spliced 
/35 variant or a different/3 subunit altogether. 
Although Tat contains an RGD sequence,  and the otv/35 
integrin has been shown to recognize the RGD sequence in 
vitronectin and in  some peptides  (Cheresh  et  al.,  1989; 
Freed et al., 1989; Smith et al., 1990), our results show that 
the integrin recognition sequence in Tat is the basic domain 
of Tat, not RGD. This conclusion is based on the complete 
correlation we found between the presence of the basic do- 
main in the various Tat peptides and their ability to support 
cell  attachment and to  bind  the  av/35 integrin in  affinity 
chromatography. In contrast, the presence or absence of the 
RGD sequence had no influence in either type of assay. Ap- 
parently, the RGD sequence is present in a context not suit- 
able for binding any of the integrins present on the cells we 
used, because even the ot~/33  integrin, which is the best binder 
of short RGD-containing peptides (e.g., Fig. 4),  failed to 
bind appreciably to the RGD-containing Tat peptides. The 
binding of the Tat basic domain by the tx,/35 integrin, there- 
fore, appears to be a function distinct from the RGD binding. 
In addition to utilizing a basic domain, the new interaction 
of otv/35 has other unusual features. First, it is stable in the 
presence of 10 mM EDTA, whereas other integrin-ligand in- 
teractions, including the binding of otv/55 to the RGD  se- 
quence of vitronectin, typically require divalent cations and 
are inhibited by the presence of EDTA (Pytela et al., 1987; 
Busk et al.,  1992).  Another characteristic of the basic do- 
main binding of the otv/~5 integrin is that it was inhibited by 
NaC1 concentrations above the physiological concentration. 
Although the concept of a salt-sensitive binding site for a ba- 
sic peptide is unusual for integrin-ligand interactions, it is 
not without precedent. The ot3/3t integrin binds to collagen, 
fibronectin and laminin; the collagen and fibronectin binding 
is salt-sensitive (Wayner and Carter, 1987) and may therefore 
be  equivalent to  the  binding of cry/35 to  basic  sequences 
demonstrated here. In fact, the binding of Ota/31 to laminin 
has been found to be mediated by a basic sequence in laminin 
(Gehlsen et al., 1992). Furthermore, a recent study suggests 
that integrin-mediated binding of avian neural crest cells to 
laminin can be independent of divalent cations (LaUier and 
Bronner-Fraser,  1991), which  is  another  characteristic 
shared by the basic sequence binding site in ctd35. 
These differences between the binding sites for the RGD 
and basic sequences in otv/$5, in addition to the fact that we 
were unable to inhibit basic domain-mediated cell attach- 
ment with a mAb that inhibits the RGD-mediated binding of 
ot~/35 to vitronectin, suggest that this integrin has two sepa- 
rate binding sites. The concept of two distinct ligand binding 
sites has been suggested for the tx4/31 and tx4/37 integrins. 
Each of these two integrins has a binding site for the en- 
dothelial cell ligand, V-CAM, and another binding site for 
an alternatively spliced segment of fibronectin (Elices et al., 
1990;  Rtiegg et al.,  1992).  The data on the cz3/~t integrin 
discussed above and our finding of/31  integrin binding to 
peptide columns comprised entirely of  arginine or lysine also 
support the notion that at least some of the/3t integrins also 
contain a site for basic domain binding. Among the/31 inte- 
grins  that  bound  to  the  polyarginine  and/or  polylysine 
columns  were  et5/31 and  ot3/3t; txs/3t binds  also  to  RGD 
(Pytela et al.,  1985a)  and the same has been reported for 
ot3/31 (Elices et al.,  1991). Finally, I/b/IIIa may also share 
some of the RGD and basic peptide binding properties of 
ot~/35, because peptides containing both an RGD and a basic 
segment bind more avidly to IIb/IIIa than peptides contain- 
ing RGD alone (Savage et al., 1990). Therefore, all integrins 
may have an RGD (or equivalent) binding site in addition to 
a basic sequence (or equivalent) binding site. 
The physiological significance of the basic sequence bind- 
ing by the otv/35 integrin remains to be elucidated, but two 
findings among our results indicate such a role. First, this 
binding appeared to make a contribution to cell attachment 
in vitro, because the attachment of our test cells to vitronec- 
tin was inhibited to a substantially greater degree by a com- 
bination of a basic peptide and an RGD peptide than by the 
RGD peptide alone. Secondly, the basic domain binding dis- 
played a specificity; the ol~/35 integrin was the only integrin 
that bound substantially to the Tat basic domain peptide, 
whereas peptides consisting of only arginine or lysine resi- 
dues as the basic amino acid primarily bound fll integrins. 
This suggests that the only nonbasic residue, a single glu- 
tamine, in the basic nine amino acid stretch of Tat may be 
important for the specificity of Tat toward ct435. This as- 
sumption is supported by the fact that the peptide from the 
basic domain of vitronectin also bound otv/35, because the 
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is the case with the Tat peptide, this residue is surrounded 
by basic residues (KKQR  in vitronectin vs.  RRQR  in Tat). 
Because the arrangement  of the basic amino acids in the two 
peptides is otherwise quite different, the exact order of the 
basic amino acids may not be important.  The specificities of 
the basic domain interactions, therefore,  do not seem to be 
as clear-cut as with some other receptor-ligand interactions. 
Whereas  the  Tat peptide  displayed  specificity  for t~v/35, 
especially in the affinity  chromatography experiments, that 
of the vitronectin peptide was intermediate between the Tat 
peptide and the peptides consisting entirely of arginine or ly- 
sine residues. We also found even cells lacking the Otv/35 in- 
tegrin to be capable of attaching  to Tat (not shown). This sit- 
uation  is  reminiscent  of the  RGD  system  where  various 
RGD-directed integrins also display much overlap in spec- 
ificity (Ruoslahti,  1991). 
Finally,  it may be that the vitronectin peptide is not fully 
representative of the binding site in vitronecfin,  either be- 
cause it does not represent the entire site or because the con- 
formation of the site as a peptide is not the same as in the 
intact  protein.  An  intriguing  possibility  is  that  the  Tat- 
derived basic peptide is more active than the peptide from 
the vitronectin basic domain, because it happens to mimic 
a basic domain in an ot,/35 ligand yet to be found. 
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